African Green Monkeys Recapitulate the Clinical Experience with Replication of Live Attenuated Pandemic Influenza Virus Vaccine Candidates

ABSTRACT Live attenuated cold-adapted (ca) H5N1, H7N3, H6N1, and H9N2 influenza vaccine viruses replicated in the respiratory tract of mice and ferrets, and 2 doses of vaccines were immunogenic and protected these animals from challenge infection with homologous and heterologous wild-type (wt) viruses of the corresponding subtypes. However, when these vaccine candidates were evaluated in phase I clinical trials, there were inconsistencies between the observations in animal models and in humans. The vaccine viruses did not replicate well and immune responses were variable in humans, even though the study subjects were seronegative with respect to the vaccine viruses before vaccination. Therefore, we sought a model that would better reflect the findings in humans and evaluated African green monkeys (AGMs) as a nonhuman primate model. The distribution of sialic acid (SA) receptors in the respiratory tract of AGMs was similar to that in humans. We evaluated the replication of wt and ca viruses of avian influenza (AI) virus subtypes H5N1, H6N1, H7N3, and H9N2 in the respiratory tract of AGMs. All of the wt viruses replicated efficiently, while replication of the ca vaccine viruses was restricted to the upper respiratory tract. Interestingly, the patterns and sites of virus replication differed among the different subtypes. We also evaluated the immunogenicity and protective efficacy of H5N1, H6N1, H7N3, and H9N2 ca vaccines. Protection from wt virus challenge correlated well with the level of serum neutralizing antibodies. Immune responses were slightly better when vaccine was delivered by both intranasal and intratracheal delivery than when it was delivered intranasally by sprayer. We conclude that live attenuated pandemic influenza virus vaccines replicate similarly in AGMs and human subjects and that AGMs may be a useful model to evaluate the replication of ca vaccine candidates. IMPORTANCE Ferrets and mice are commonly used for preclinical evaluation of influenza vaccines. However, we observed significant inconsistencies between observations in humans and in these animal models. We used African green monkeys (AGMs) as a nonhuman primate (NHP) model for a comprehensive and comparative evaluation of pairs of wild-type and pandemic live attenuated influenza virus vaccines (pLAIV) representing four subtypes of avian influenza viruses and found that pLAIVs replicate similarly in AGMs and humans and that AGMs can be useful for evaluation of the protective efficacy of pLAIV.

[1]  G. Air,et al.  Glycomic Analysis of Human Respiratory Tract Tissues and Correlation with Influenza Virus Infection , 2013, PLoS pathogens.

[2]  Robert B. Couch,et al.  A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine , 2012, PloS one.

[3]  M. Katze,et al.  Integrated Clinical, Pathologic, Virologic, and Transcriptomic Analysis of H5N1 Influenza Virus-Induced Viral Pneumonia in the Rhesus Macaque , 2012, Journal of Virology.

[4]  D. Jarvis,et al.  Letter to the Glyco-Forum: Effective glycoanalysis with Maackia amurensis lectins requires a clear understanding of their binding specificities , 2011 .

[5]  R. Karron,et al.  An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. , 2011, Vaccine.

[6]  B. Murphy,et al.  Identification of Human Parainfluenza Virus Type 2 (HPIV-2) V Protein Amino Acid Residues That Reduce Binding of V to MDA5 and Attenuate HPIV-2 Replication in Nonhuman Primates , 2011, Journal of Virology.

[7]  K. Subbarao,et al.  Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine , 2011, Proceedings of the National Academy of Sciences.

[8]  Pradeep Kota,et al.  Automated minimization of steric clashes in protein structures , 2011, Proteins.

[9]  Grace L. Chena,et al.  Seasonal in fl uenza infection and live vaccine prime for a response to the 2009 pandemic H 1 N 1 vaccine , 2011 .

[10]  T. Songserm,et al.  Avian and human influenza A virus receptors in trachea and lung of animals. , 2010, Asian Pacific journal of allergy and immunology.

[11]  K. Subbarao,et al.  A Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and Monkeys , 2010, Journal of Virology.

[12]  J. P. Long,et al.  Extrapulmonary tissue responses in cynomolgus macaques (Macaca fascicularis) infected with highly pathogenic avian influenza A (H5N1) virus , 2010, Archives of Virology.

[13]  Hideo Goto,et al.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses , 2009, Nature.

[14]  R. Karron,et al.  Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. , 2009, Vaccine.

[15]  R. Karron,et al.  A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. , 2009, Vaccine.

[16]  Y. Kawaoka,et al.  Immunogenicity and Protective Efficacy of a Live Attenuated H5N1 Vaccine in Nonhuman Primates , 2009, PLoS pathogens.

[17]  G. Leroux-Roels,et al.  Current status and progress of prepandemic and pandemic influenza vaccine development , 2009, Expert review of vaccines.

[18]  Carole R. Baskin,et al.  Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus , 2009, Proceedings of the National Academy of Sciences.

[19]  R. Karron,et al.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. , 2009, The Journal of infectious diseases.

[20]  S. Dunham,et al.  Differences in influenza virus receptors in chickens and ducks: Implications for interspecies transmission , 2009, Journal of molecular and genetic medicine : an international journal of biomedical research.

[21]  K. Subbarao,et al.  Live attenuated vaccines for pandemic influenza. , 2009, Current topics in microbiology and immunology.

[22]  K. Subbarao,et al.  Evaluation of Live Attenuated Influenza A Virus H6 Vaccines in Mice and Ferrets , 2008, Journal of Virology.

[23]  I. Wilson,et al.  Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. , 2008, Journal of molecular biology.

[24]  G. Leroux-Roels,et al.  An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. , 2008, The Journal of infectious diseases.

[25]  K. Subbarao,et al.  A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. , 2008, Virology.

[26]  M. Zambon,et al.  Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. , 2008, Vaccine.

[27]  G. Air,et al.  Evolving complexities of influenza virus and its receptors. , 2008, Trends in microbiology.

[28]  A. J. Bourne,et al.  Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses , 2007, Respiratory research.

[29]  Ron A M Fouchier,et al.  Immunopathology and Infectious Disease Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals , 2010 .

[30]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[31]  Y. Guan,et al.  Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract , 2007, Nature Medicine.

[32]  R. Couch,et al.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Yu Wang,et al.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial , 2006, The Lancet.

[34]  B. Murphy,et al.  Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets , 2006, PLoS medicine.

[35]  M. Zambon,et al.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial , 2006, The Lancet.

[36]  Ian A. Wilson,et al.  Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus , 2006, Science.

[37]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[38]  Yoshihiro Kawaoka,et al.  Avian flu: Influenza virus receptors in the human airway , 2006, Nature.

[39]  James C Paulson,et al.  Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. , 2006, Journal of molecular biology.

[40]  Yi Guan,et al.  Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003 , 2005, Journal of Clinical Microbiology.

[41]  B. Murphy,et al.  Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. , 2005, Vaccine.

[42]  M. St. Claire,et al.  Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys , 2004, Virology.

[43]  A. Razmpour,et al.  LIVE ATTENUATED INFLUENZA VACCINE INDUCES CROSS-REACTIVE ANTIBODY RESPONSES IN CHILDREN AGAINST AN A/FUJIAN/411/2002-LIKE H3N2 ANTIGENIC VARIANT STRAIN , 2004, The Pediatric infectious disease journal.

[44]  Carole R. Baskin,et al.  Integration of Clinical Data, Pathology, and cDNA Microarrays in Influenza Virus-Infected Pigtailed Macaques (Macaca nemestrina) , 2004, Journal of Virology.

[45]  A. Osterhaus,et al.  For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .

[46]  J. Peiris,et al.  Re-emergence of fatal human influenza A subtype H5N1 disease , 2004, The Lancet.

[47]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Kendal.  Cold-adapted live attenuated influenza vaccines developed in Russia: Can they contribute to meeting the needs for influenza control in other countries? , 1997, European Journal of Epidemiology.

[49]  David Swayne,et al.  Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. , 2003, Vaccine.

[50]  H. Park,et al.  Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. , 2003, Vaccine.

[51]  T. Kuiken,et al.  A Primate Model to Study the Pathogenesis of Influenza A (H5N1) Virus Infection , 2003, Avian diseases.

[52]  T. Kuiken,et al.  Pathology of Human Influenza A (H5N1) Virus Infection in Cynomolgus Macaques (Macaca fascicularis) , 2003, Veterinary pathology.

[53]  T. Kuiken,et al.  Pathogenesis of Influenza A (H5N1) Virus Infection in a Primate Model , 2001, Journal of Virology.

[54]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[55]  M. Peiris,et al.  Human infection with influenza H9N2 , 1999, The Lancet.

[56]  Y. Guo,et al.  [Discovery of men infected by avian influenza A (H9N2) virus]. , 1999, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[57]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[58]  A. Monto,et al.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. , 1993, The Journal of infectious diseases.

[59]  B. Murphy,et al.  Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus , 1986, Journal of clinical microbiology.

[60]  R. Webster,et al.  Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. , 1982, Science.

[61]  R. Webster,et al.  Virulence of Avian Influenza A Viruses for Squirrel Monkeys , 1982, Infection and immunity.

[62]  Pamela G. Guren,et al.  Candidates , 1982 .

[63]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .